| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 23rd February 2021 | Frederick W Driscoll | 25,000 | Open or private sale | $4.03 | $100,625.00 |
| 5th February 2021 | Richard Adcock | 150,000 | Exercise of derivative | $0.00 | |
| 5th February 2021 | Barry J. Simon | 22,100 | Exercise of derivative | $2.00 | $44,164.64 |
| 5th February 2021 | Richard Adcock | 68,171 | Payment by withholding | $23.72 | $1,617,016.12 |
| 5th February 2021 | Barry J. Simon | 22,100 | Open or private sale | $23.09 | $510,266.90 |
| 2nd February 2021 | Barry J. Simon | 82,070 | Open or private sale | $20.65 | $1,694,802.95 |
| 2nd February 2021 | Barry J. Simon | 82,070 | Exercise of derivative | $2.00 | $164,008.69 |
| 22nd December 2020 | Barry J. Simon | 130,000 | Exercise of derivative | $2.00 | $259,792.00 |
| 22nd December 2020 | Barry J. Simon | 130,000 | Open or private sale | $18.05 | $2,346,604.00 |
| 10th December 2020 | John C Thomas | 42,592 | Open or private sale | $10.83 | $461,122.29 |
Nant Kwest
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
NantKwest, Inc. engages in the development of immunotherapies. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.
Ticker: NK
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1326110
Employees: 148
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $103 M (0%)
Other Assets, Current: $67 Th (179%)
Assets, Current: $115 M (106%)
Property, Plant and Equipment, Net: $59 M (0%)
Other Assets, Noncurrent: $3 M (0%)
Assets: $196 M (37%)
Accounts Payable, Current: $4 M (127%)
Accrued Liabilities, Current: $7 M (0%)
Liabilities, Current: $17 M (47%)
Liabilities: $27 M (18%)
Common Stock, Value, Issued: $11 Th (10%)
Common Stock, Shares, Issued: $108 M (9%)
Additional Paid in Capital, Common Stock: $870 M (11%)
Retained Earnings (Accumulated Deficit): $701 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $100 Th (-4%)
Stockholders' Equity (Parent): $170 M (0%)
Liabilities and Equity: $196 M (37%)
Research and Development: $14 M (-49%)
Operating Income/Loss: $20 M (-47%)
Other Income, net: $139 Th (-59%)
Provision for income taxes: $4 Th (0%)
